Efikasi Penggunaan GnRH pada Luaran Prosedur IVF

Oleh :

dr.Akbar Novan Dwi Saputra, SpOG

Penggunaan gonadotropin releasing-hormon (GnRH) sebelum IVF dapat mempengaruhi live birth pasien dengan subfertilitas. Stimulasi protokol in vitro fertilization (IVF) sudah banyak di teliti dan digunakan oleh spesialis obstetri dan ginekologi. Akan tetapi, hingga saat ini, belum ada standar terapi yang dikeluarkan.

Prosedur IVF telah lama dilakukan sejak live birth dan transfer embrio pertama sejak 1978. Awalnya, IVF diindikasikan pada wanita infertil dengan oklusi tuba, tetapi seiring dengan berkembangnya waktu terdapat beberapa perubahan indikasi dilakukan IVF. Saat ini, IVF diindikasikan pada pasangan dengan subfertilitas yang tidak dapat dijelaskan, faktor servikal, kegagalan induksi ovulasi, endometriosis atau patologi tuba unilateral.[1,13]

IVF dan Controlled Ovarian Hyperstimulation

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. van Loendersloot LL, van Wely M, Limpens J, Bossuyt PM, Repping S, van der Veen F. Predictive factors in in vitro fertilization (IVF): a systematic review and meta-analysis. Hum Reprod Update. 2010;16(6):577-589. doi:10.1093/humupd/dmq015
2. Troude P, Bailly E, Guibert J, et al. Spontaneous pregnancies among couples previously treated by in vitro fertilization. Fertil Steril 2012; 98:63.
3. DiVasta AD, Feldman HA, Sadler Gallagher J, et al. Hormonal Add-Back Therapy for Females Treated With Gonadotropin- Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial. Obstet Gynecol 2015;126:617.
4. Roque M, Valle M, Guimarães F ,et al. Freeze-all policy: fresh vs frozen-thawed embryo transfer. Fertil Steril 2015;103:1190.
5. Yeh JS, steward RG, Dude Am, et al. Pregnancy rates in donor oocytes cycles compared to similar autologous in vitro fertilization cycles: an analysis of 26, 457 fresh cycles from the society for Assisted Reproductive Technology. Fertil Steril 2014; 102:399.
6. Chung K, Fogle R, Bendikson K, et al. Microdose gonadotropin-releasing hormone agonist in the absence of exogenous gonadotropins is not sufficient to induce multiple follicle development. Fertl Steril 2011;95:317
7. Maheswari A, Gibreel A, Siristadis CS, Bhattacharya S. Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database Syst Rev 2011; CD006919.
8. Al-Inany HG, Youssef MA, Ayeleke RO, et al. Gonadotropin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2016; 4: CD001750.
9. Albuquerque LE, Tso LO, Saconato H, et al. Depot versus daily administration of gonadotropin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles. Cochrane Database Syst Rev 2013;CD002808.
10. Youssef MA, Abou-Setta AM, Lam WS. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database Syst Rev 2016;4: CD003719.
11. Youssef MA, Van der Veen F, Al-Inany HG, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev 2014; CD008046.
12. Surry ES, Soliman AM, Agarwal SK, et al. Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis. Fertl Steril 2019;112:298.
13. Castillo JC, Haahr T, Martínez-Moya M, Humaidan P. Gonadotropin-releasing hormone agonist for ovulation trigger - OHSS prevention and use of modified luteal phase support for fresh embryo transfer. Ups J Med Sci. 2020 May;125(2):131-137. doi: 10.1080/03009734.2020.1736696. Epub 2020 May 4. PMID: 32366146; PMCID: PMC7721056.